HD-OPM Archive
Topics › Lp(a)

Single-dose Lp(a) therapy cut Lp(a) by more than 94% for nearly a year in a phase 1 trial

Louis Nervegna · Dec 10, 2024 · ♥ 22 reactions · 9 comments · original Facebook post
Lp(a)PCSK9, ezetimibe & newer drugs
AI summary & key facts

Louis links a Cleveland Clinic report of a phase 1 trial in which a single dose of an experimental therapy lowered lipoprotein(a) by more than 94%, with effects lasting nearly a year.

94% reduction in Lp(a) for nearly 1 year.

Cleveland ClinicTrial Shows a Single Dose of an Experimental Therapy Reduces Lipoprotein(a), an Important Heart Disease Risk Factor, More than 94% for Nearly a YearFindings from a phase 1 trial reported by a Cleveland Clinic physician show that a single dose of an experimental therapy produced greater than 94% reductions in blood levels of lipoprotein(a), a key driver of heart disease risk, with the results lasting for nearly a year. Results from the “Efficacy and Safety of Lepodisiran: An … Read Morenewsroom.clevelandclinic.org

Research cited

#heartdisease#riskfactors#clevelandclinic
← newer: 25 statin RCTs: about 75 mg/dL LDL lowering cut heart attackolder: Sabatini on diet and mTOR: limit amino acids and insulin; ~1 →